Oppenheimer & Co. Inc. Cuts Stake in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Oppenheimer & Co. Inc. decreased its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 3.8% in the 3rd quarter, HoldingsChannel.com reports. The fund owned 18,345 shares of the medical equipment provider’s stock after selling 720 shares during the quarter. Oppenheimer & Co. Inc.’s holdings in Intuitive Surgical were worth $9,012,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Vanguard Group Inc. lifted its position in shares of Intuitive Surgical by 1.6% during the 1st quarter. Vanguard Group Inc. now owns 30,868,620 shares of the medical equipment provider’s stock worth $12,319,358,000 after purchasing an additional 493,126 shares during the last quarter. Capital World Investors boosted its holdings in Intuitive Surgical by 1.0% in the first quarter. Capital World Investors now owns 7,284,269 shares of the medical equipment provider’s stock valued at $2,907,079,000 after purchasing an additional 73,634 shares in the last quarter. Baillie Gifford & Co. increased its stake in Intuitive Surgical by 0.6% in the third quarter. Baillie Gifford & Co. now owns 3,848,547 shares of the medical equipment provider’s stock valued at $1,890,676,000 after purchasing an additional 24,183 shares during the last quarter. American Century Companies Inc. raised its holdings in Intuitive Surgical by 3.0% during the second quarter. American Century Companies Inc. now owns 2,398,193 shares of the medical equipment provider’s stock worth $1,066,837,000 after purchasing an additional 70,556 shares in the last quarter. Finally, Clearbridge Investments LLC lifted its position in shares of Intuitive Surgical by 1.6% during the 2nd quarter. Clearbridge Investments LLC now owns 1,981,297 shares of the medical equipment provider’s stock worth $881,380,000 after buying an additional 30,449 shares during the last quarter. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the stock. The Goldman Sachs Group set a $604.00 price target on shares of Intuitive Surgical in a research note on Friday, October 18th. Oppenheimer reiterated a “market perform” rating on shares of Intuitive Surgical in a research report on Friday, October 18th. Robert W. Baird upped their target price on Intuitive Surgical from $503.00 to $565.00 and gave the company an “outperform” rating in a research report on Thursday, October 17th. Citigroup raised their price target on Intuitive Surgical from $512.00 to $560.00 and gave the stock a “buy” rating in a research note on Thursday, August 22nd. Finally, Truist Financial boosted their price objective on Intuitive Surgical from $520.00 to $570.00 and gave the company a “buy” rating in a research note on Monday, October 14th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and fourteen have assigned a buy rating to the stock. According to data from MarketBeat.com, Intuitive Surgical presently has an average rating of “Moderate Buy” and a consensus target price of $513.74.

Insiders Place Their Bets

In other Intuitive Surgical news, insider Jamie Samath sold 269 shares of the stock in a transaction on Monday, November 11th. The stock was sold at an average price of $539.89, for a total value of $145,230.41. Following the completion of the transaction, the insider now owns 8,757 shares in the company, valued at approximately $4,727,816.73. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, insider Jamie Samath sold 269 shares of the firm’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $539.89, for a total value of $145,230.41. Following the completion of the sale, the insider now owns 8,757 shares in the company, valued at $4,727,816.73. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Henry L. Charlton sold 40,243 shares of the company’s stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $486.84, for a total transaction of $19,591,902.12. Following the transaction, the senior vice president now owns 3,001 shares in the company, valued at $1,461,006.84. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 91,178 shares of company stock worth $45,897,071. Company insiders own 0.90% of the company’s stock.

Intuitive Surgical Stock Performance

Shares of ISRG opened at $536.69 on Thursday. The stock has a market capitalization of $191.16 billion, a P/E ratio of 86.28, a P/E/G ratio of 5.28 and a beta of 1.39. Intuitive Surgical, Inc. has a 1 year low of $287.98 and a 1 year high of $542.59. The company’s fifty day moving average is $495.85 and its two-hundred day moving average is $455.08.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings results on Thursday, October 17th. The medical equipment provider reported $1.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.24 by $0.32. The business had revenue of $2.04 billion for the quarter, compared to analyst estimates of $2.01 billion. Intuitive Surgical had a net margin of 28.51% and a return on equity of 13.41%. Sell-side analysts predict that Intuitive Surgical, Inc. will post 5.45 EPS for the current year.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.